Anebulo's ANEB-001 meets primary endpoint in Phase 2 ACI trial (p<0.0001)

Anebulo Pharmaceuticals, Inc.

Primary endpoint VAS 'Feeling High' met (p<0.0001) for both 50mg and 100mg ANEB-001 vs placebo.
Only 10% (50mg) and 30% (100mg) reported feeling high vs 75% placebo (p<0.001).
ANEB-001 well tolerated; all AEs mild/transient except one moderate nausea/vomiting in 50mg group.
Part B of study planned for Q3 2022; U.S. IND submission expected by end of 2022.
Conference call at 8:30am ET today to discuss topline results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.